Epithelial ovarian cancer is the fifth most common cause of cancer death in women (Parkin et al., 1988) . Despite improvements in treatment resulting in increasing response rates, relapse-free survival and overall survival since the introduction of platinum chemotherapy and its derivatives, such as carboplatin, a large proportion of women are still not being cured of their disease.
One approach to improving these results is to consider the use of drug regimens that deliver dose-intensive therapy. The relationship between the dose intensity of chemotherapy and survival in patients with ovarian carcinoma remains controversial. A randomised study comparing a standard dose combined chemotherapy regimen with treatment given at half dose intensity but the same total dose was carried out by our group. The patients receiving the lower dose intensity had a significantly lower response rate and more patients progressed during therapy. However, overall survival was not significantly different (Murphy et al., 1993) . Other prospective randomised trials have been reported examining standard dose vs higher dose chemotherapy as first-line treatment for epithelial ovarian cancer. In a randomised comparison by the Gynaecology Oncology Group (GOG), 485 patients with suboptimally debulked (,>1 cm) stage III or IV ovarian cancer received either four cycles of cisplatin 100 mg m-2 and cyclophosphamide 1000 mg m-2 every 3 weeks or cisplatin 50 mg m-2 and cyclophosphamide 500 mg m-2 for eight cycles. The received dose intensity ratio was 0.91:0.46, i.e. 2:1, while the total dose was the same for the two arms. Response, median progression-free interval and survival rates were similar but toxicity was greater in the dose-intensive arm (McGuire et al., 1992) . Similar results were reported by Colombo et al. (1993) comparing cisplatin 50 mg m-2 weekly for nine cycles with cisplatin 75 mg m-2 every 3 weeks for six cycles. The dose intensity ratio was 2:1 and the total dose remained constant. The Italian Group for Clinical Research have reported a randomised trial of 101 patients comparing cisplatin 100 mg m-2 weekly with a 5 week interval between the third and fourth cycles with cisplatin 100 mg m-2 every 3 weeks for six cycles. The dose-intensity ratio was 1.6:1, and again total dose was equivalent in the two arms. Overall response and survival rates in the first 2 years were similar, but survival diverged thereafter in favour of the dose intensive arm, with the odds in the risk of dying at 8 years of 0.10 (P=0.03) (Bella et al., 1994) .
There are two reports of randomised trials in which higher dose intensity and total dose have been associated with a survival advantage (Kaye et al., 1992; Ngan et al., 1989) . Dose intensity and total dose may both contribute to improved response and survival, but there remains considerable uncertainty regarding the possible benefit of doseintensive chemotherapy in patients with ovarian cancer and further studies are warranted.
Over recent years haemopoietic growth factors, such as G-CSF, have been used increasingly in an attempt to overcome one of the major dose-limiting side-effects of high-dose chemotherapy treatment, namely prolonged neutropenia. Calvert et al. (1994) demonstrated that the dose of carboplatin could be escalated up to a target area under the curve (AUC) of 9 mg ml-' min-' every 2 weeks for four cycles. However, thrombocytopenia became the dose-limiting toxicity with >50% of cycles requiring platelet transfusions at this AUC. Further dose escalation will not be possible with G-CSF alone, since this agent has no effect on doselimiting thrombocytopenia.
Peripheral blood progenitor cells have, over recent years, proved a convenient alternative to bone marrow transplantation following myeloablative chemotherapy, and their use following high-dose chemotherapy leads to earlier recon stitution of both white cell and platelet counts than with Correspondence: A Weaver Received 30 April 1996; revised 26 June 1996; accepted 27 June 1996 bone marrow infusions (Juttner et al., 1992) . Priming patients with haemopoietic growth factors, with or without chemotherapy, enhances the yield of progenitor cells (Socinski et al., 1988; Duhrsen et al., 1988; Gianni et al., 1989) and the apheresis product obtained may be divided into aliquots and reinfused following several cycles of doseintensive chemotherapy in order to support the patients' neutrophil and platelet count. More recently, investigators have studied the mobilisation of progenitor cells in healthy donors by the administration of haemopoietic growth factors alone. The apheresis products from these healthy donors have been used to support patients following allogeneic transplantation (Russell et al., 1993) .
We have investigated the mobilisation of blood progenitor cells using G-CSF alone in previously untreated ovarian cancer patients, followed by the same patients being treated with chemotherapy and G-CSF in order to compare the mobilising effect of the two regimens. The study was also able to determine whether an approximately 200% increase in dose intensity over standard dose carboplatin and cyclophosphamide could be safely administered with few side-effects using G-CSF and blood progenitor cell support in patients with ovarian carcinoma.
Patients, materials and methods Patients
Previously untreated patients aged between 16 and 65 years with histologically proven epithelial ovarian cancer, International Federation of Gynaecology and Obstetrics (FIGO) stage Ic-IV were entered. All eligible patients were required to have a normal full blood count. In addition, patients' glomerular filtration rate (GFR) (measured using 51Cr-EDTA clearance) had to be greater than 50 ml min-'. Fourteen -patients were treated between April and September 1994. The study was approved by South Manchester District Ethics Committee and all patients gave written informed consent for entry into the trial. A group of previously treated ovarian cancer patients who received our standard dose chemotherapy regimen was evaluated for comparison.
Treatment
All patients were initially treated with human recombinant G-CSF (filgrastim) 10 ,ug kg-1 day-' subcutaneously (s.c.) for 6 days before the first single apheresis (phase A). This apheresis product was frozen and stored in liquid nitrogen for use in patients whose blood count failed to recover following chemotherapy. Following phase A the same patients were treated with cyclophosphamide 3 g m-2and mesna 6 g m-2 given as a 4 h intravenous infusion on day 1, at least 48 h after the first apheresis. Filgrastim 5 jg kg-' day-1 was administered starting 24 h after chemotherapy until the white blood count (WBC) was 4 x l091-1, when the patients underwent a second single apheresis (phase B). The product of this harvest was divided into four aliquots and frozen in a controlled rate freezer in the vapour phase of liquid nitrogen (Kryo 10; Planer Biomed Products, Ltd. Middlesex, UK) and then transferred to liquid nitrogen and stored at -196°C.
The first seven patients were planned to receive treatment at 3 weekly intervals, and the remaining seven patients were planned to be treated at 2 weekly intervals with combined chemotherapy (carboplatin and cyclophosphamide). Carboplatin dose was prescribed according to the Calvert formula (Calvert et al., 1989) an AUC 7.5 mg ml -min-' using a GFR measurement before each cycle of treatment, i.e. carboplatin dose = 7.5 (EDTA clearance +25 mg). Carboplatin was reconstituted in 1 1 of 5% dextrose and infused over 1 h. Cyclophosphamide 900 mg m-2 was given immediately after the carboplatin, infused over 1 h in 11 of normal saline. Ondansetron and dexamethasone were routinely given as antiemetics. Each cycle of combination chemotherapy (phase C) was followed 24 h later by reinfusion of one aliquot of the patient's own progenitor cells collected during phase B. Filgrastim 5 jg kg-' day-' was recommenced 24 h later and continued until absolute neutrophil count (ANC) recovery (ANC > 1 x 109 1`for 3 consecutive days or 10 x 109 1-1 for 1 day) was achieved.
Patients received four cycles of carboplatin/cyclophosphamide combination chemotherapy following the initial cycle of single agent cyclophosphamide. Patients treated at 3 weekly intervals were only treated when their WBC > 3.0 x I 109 (or ANC > 1 x 109 1 ') and platelets > 75 x I09 1-'. If the blood count failed to recover at the time of the next planned cycle of treatment the chemotherapy was delayed until recovery had occurred. Treatments were always delivered at full dose and never dose reduced.
Patients receiving chemotherapy at 2 weekly intervals were only treated if their WBC ) 3.0x l091-' (or ANC )I x I01 1-l) and platelets )50x 1091.
Peripheral blood progenitor cells were collected on a Spectra cell separator (Cobe Laboratories, Lakewood, CO, USA) using a continuous collection procedure until 2.5 times the patient's blood volume had been processed. Platelet transfusions were given to maintain a platelet count ) 20x l09 1-and red cell transfusions to maintain a haemoglobin count of > 8 g dl l.
Prestudy procedures All patients were assessed by full physical examination, including height, weight, vital signs, Karnofsky performance status, full blood count, biochemistry (including liver function tests), serum Ca 125, GFR (5'Cr-EDTA clearance) and computerised tomography (CT) scan of abdomen and pelvis.
Study procedures Full blood counts, including manual different counts, were performed as follows: phase A: days -7, -3, -2 and -1; phase B: days 1, 8, 10, 12, 14, 16, 18 and 20; phase C: twice weekly.
Serum biochemistry and Ca 125 levels were measured on day 1 of each cycle of chemotherapy. Progenitor cell assessments (CFU-GM, BFU-E colony assays and CD34+ cell counts) were performed on peripheral blood samples on the same days as the full blood counts described above and also on the apheresis products from phases A and B.
Clonogenic progenitor cell assay Ficoll-separated cells from the peripheral blood or apheresis product were plated in modified Eagle's medium supplemented with penicillin and streptomycin and 0.66% (w/v) agarose and overlayed on a gelled layer of modified Eagle's medium supplemented with purified growth factors (rhSCF, rhIL-3, rhIL-6 and rhGM-CSF at final concentrations of 50 ng ml-' for CFU-GM assay, and rhSCF, rhIL-3, rhIL-6 and rhEPO15 min, the red cells then lysed (Ortho- Apheresis product and peripheral blood The results of peripheral blood progenitor cell mobilisation using filgrastim (10 pg kg-') alone before chemotherapy compared with cyclophosphamide followed by filgrastim (5 ,g kg-') in the apheresis product are shown in Table I . There was no significant difference in progenitor cell yields, in terms of CFU-GM, BFU-E or CD34 cells, between the two different mobilisation regimens. However, there was a significant difference between the two regimens in terms of mononuclear cell numbers mobilised. There were almost three times as many mononuclear cells in the apheresis product of the previously untreated patients following filgrastim alone compared with yields using filgrastim We intended to treat seven patients at 2 weekly intervals but of these only two patients completed their treatment as planned. Two patients had a delay of 1 week, for one cycle and each of the remaining three patients had three delays of 1 week for each of the last three cycles. All the delays were due to inadequate recovery of the platelet count. The doselimiting toxicity of the 2 weekly regimen was thrombocytopenia. In this cohort of patients only 61% of chemotherapy was delivered on time and at full dose. The median average relative dose intensity actually delivered for this group was 2.33 compared with an intended average relative dose intensity of 2.63; less than 30% of patients treated at 2 weekly intervals received their planned dose intensity (Table  III) .
In order to put the results of the dose-intensive arms of the study into context we have analysed a different group of ten patients treated with standard dose carboplatin (AUC 5 mg ml-' min-') and cyclophosphamide (600 mg m-2) for six cycles, during the same period as those patients receiving dose-intensive treatment. Of these ten patients receiving standard treatment only two completed all planned cycles without any delay, i.e. 80% required at least one delay during treatment. Out of a total of 60 cycles of treatment, 22 cycles were delayed resulting in a median average relative dose intensity of 0.91 and only 56% of the planned average dose intensity delivered (Table III) .
Neutropenic fever and haematological toxicity Five of the 14 patients developed neutropenic fever (defined as fever greater than 38°C and neutrophil count < 1.0 x 109 1l) requiring hospital admission and intravenous antibiotics using our standard policy. In four patients this occurred following cyclophosphamide 3 g m-2 (phase B mobilisation). A further patient developed neutropenic fever during phase C treatment. There was no documented evidence of sepsis and all febrile patients had negative blood Dose-intensive 1825 cultures. The one patient developing neutropenic fever during treatment phase C was being treated at 2 weekly intervals. All patients recovered following intravenous antibiotics and no patient required a delay in planned chemotherapy as a result of these episodes. All patients experienced grade 4 toxicity following cyclophosphamide 3 g m-2 during phase B with nadir white blood counts < 1.0 x 109 1-I with corresponding absolute neutrophil counts <0.5 x 1091-'. Table IV shows the median nadir white blood counts, absolute neutrophil and platelet counts and their ranges during the four cycles of carboplatin/cyclophosphamide (phase C) of treatment for the two groups of patients. The median WBC, ANC and platelet counts were generally higher for the patients treated at 3 weekly intervals compared with the equivalent cycle for the patients treated at 2 weekly intervals. No patient at any stage during the course of the study required the use of the reserve harvest from phase A.
Non-haematological toxicities One patient was withdrawn 3 days after entry owing to a skin reaction associated with filgrastim administered at Patients treated with the 2 weekly dose-intensive regimen suffered more delays compared with the 3 weekly doseintensive regimen. Only two of the seven patients (29%) received their planned treatment on time and at full dose. Of the 35 cycles of chemotherapy delivered to this group of patients, 11 had to be delayed, all due to thrombocytopenia. We have reached the maximum tolerated dose by administering this dose-intensive regimen at 2 weekly intervals, with only 61% of planned cycles being delivered on time. Unless the platelet count can be supported further during the administration of such dose-intensive regimens it will not be possible to escalate the dose beyond 2 weekly therapy using this regimen. Although thrombocytopenia was dose limiting in the 2 weekly regimen, subjective toxicity and other haematological toxicities were no different from the 3 weekly therapy. The dose-intensive regimens described in the paper were equally as well tolerated as the standard regimen. However, increasing the dose intensity further would be less tolerable.
The overall response rate for the study patients was 70%, with 35% achieving complete remission, although care should be taken not to overinterpret these figures in view of the small numbers of patients involved.
Our study has demonstrated that 3 weekly dose-intensive chemotherapy can be administered safely with very low, and hence acceptable, levels of toxicity using peripheral blood progenitor cells and filgrastim support. However, escalating the dose intensity using a 2 weekly schedule resulted in less than a third of patients receiving their treatment as planned owing to thrombocytopenia. The 3 weekly dose-intensive schedule with double the dose intensity of our standard chemotherapy provides a regimen for evaluating the role of dose-intensive chemotherapy in patients with ovarian carcinoma within the context of a randomised trial with similar adverse effects in both treatment arms.
